SPLIO
14.3.2023 08:01:58 CET | Business Wire | Press release
Splio, CRM expert and developer of the SaaS Individuation® marketing platform, is proud to announce the acquisition of Tinyclues, the specialist in SaaS predictive marketing based on deep learning AI. This acquisition fulfills a shared ambition to enable brands to easily orchestrate large-scale, hyper-personalized marketing plans.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230314005122/en/
On the left, David Bessis (Tinyclues) and on the right, Mireille Messine (Splio) (Photo: Splio)
Splio works with more than 400 brands, including Decathlon, Longchamp and Orange, and has been developing its own Individuation® marketing solution since 2021. Based on machine learning (AI), this solution addresses the dual challenge currently faced within CRM: how to personalize the customer experience for each individual whilst offering marketers a simple solution for large-scale orchestration.
The technological power of the Tinyclues platform increases the value proposition of Splio. A recent winner of both the Sammy and MarTech Breakthrough awards, Tinyclues is currently the most powerful predictive engine on the market, since it is the only one fueled by deep learning. It allows for the automated processing of huge volumes of first-party data for precise customer behaviour prediction. Over 100 brands use Tinyclues on a daily basis, including Veepee, Fnac, Accor, Samsung, Tiffany & Co and SNCF Connect.
The acquisition of Tinyclues thus enables Splio to establish itself as the European leader in AI-powered CRM thanks to its Individuation® marketing software, which can be rapidly and easily deployed across all industries and for companies of all sizes.
“AI has become the new standard for better understanding customers and personalizing large-scale marketing communications regardless of industry or business size. Individuation® marketing based on machine learning was an initial response to these challenges. The Tinyclues platform, based on deep learning, strengthens our leadership, and provides new opportunities for sectoral and geographical growth.” Mireille Messine, CEO of Splio.
“For a long time, Splio and Tinyclues have shared the same vision of CRM and the same ‘one-to-one at scale’ ambition for clients. Joining Splio enables our deep learning platform to express its full potential by allowing brands to carry out predictive marketing, including customer management and activation.” David Bessis, CEO of Tinyclues.
As a result of this acquisition, Splio now has 250 employees in Europe and the MEA and a portfolio of 500 business clients, from medium-sized companies to large groups from a large range of industries (retail, restaurant, telecoms, travel, hotel, leisure, etc.) with an annual recurring revenue over €30m.
About Splio
Splio is a Martech company headquartered in Paris, with 200 employees, 90 of whom work in Product and R&D, and five offices in Europe and the MEA.
Splio provides a SaaS Individuation® marketing platform to B2C customer marketing professionals. The company has a portfolio of more than 400 brands, from medium-sized enterprises to major groups from four key industries (retail, e-commerce, restaurant and telecom), including Longchamp, Decathlon, Rue du Commerce, Nicolas, Brioche Dorée and Orange.
Splio aims to empower marketing automation with Individuation® enabling companies to activate and engage each of their customers on a case-by-case basis in a unique relationship using AI.
The Individuation® marketing platform is based on a one-of-a-kind innovation that automates each day the most relevant communications to the most appropriate channels for each one of a companies’ customers. The platform is uniquely capable of calculating the optimum based both on a company’s objectives and on the appetencies of each of its customers.
Mireille Messine is the CEO of Splio and Gregory Chapron the Co-CEO. Investors include Sofiouest, Ring Capital, BPI-FAN, Omnes, Seventure, Amundi PEF, BNP Paribas Développement and SWEN.
About Tinyclues
Tinyclues is a Martech company whose precision-AI targets individuals based on buying propensity. Over 100 brands currently use the solution, including Veepee, Fnac, Accor, Samsung, Tiffany & Co and SNCF Connect.
Tinyclues’ cutting-edge technology analyses often-ignored first-party data signals so that CRM teams can accurately predict customer purchase intent and easily orchestrate complex marketing plans.
Tinyclues was the winner of the Sammy Award for Product of the Year in 2021 and the Martech Breakthrough Award for Best CRM Solution for Enterprises in 2021 and 2022. Tinyclues has been listed as a ‘Vendor to Watch’ in Gartner’s Magic Quadrant for Digital Marketing Analytics and as a ‘Cool Vendor’ within its Multichannel Marketing Report. In addition, G2 awarded Tinyclues the ‘Users Love Us’ and ‘High Performer’ certificates in 2021 and 2022.
Tinyclues’ investors include ISAI, Elaia, Alven Capital and EQT Ventures.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005122/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
